What is William Blair’s Estimate for Danaher Q3 Earnings?

Danaher Co. (NYSE:DHR) – Research analysts at William Blair decreased their Q3 2025 earnings per share estimates for shares of Danaher in a note issued to investors on Monday, January 13th. William Blair analyst M. Larew now forecasts that the conglomerate will post earnings per share of $1.92 for the quarter, down from their prior estimate of $1.97. The consensus estimate for Danaher’s current full-year earnings is $7.50 per share.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the firm posted $2.02 earnings per share. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis.

DHR has been the topic of several other reports. KeyCorp increased their price objective on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Raymond James reduced their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Citigroup cut their price objective on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a research note on Monday, January 6th. TD Cowen boosted their price target on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Finally, Stifel Nicolaus increased their price objective on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Stock Performance

NYSE DHR opened at $237.78 on Thursday. Danaher has a 52-week low of $222.53 and a 52-week high of $281.70. The company has a fifty day moving average of $235.27 and a 200-day moving average of $253.56. The company has a market capitalization of $171.74 billion, a P/E ratio of 45.38, a P/E/G ratio of 4.32 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Decker Retirement Planning Inc. purchased a new position in Danaher in the 4th quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Danaher in the third quarter worth $39,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher during the third quarter valued at $40,000. FSA Wealth Management LLC purchased a new stake in shares of Danaher during the third quarter valued at $50,000. Finally, Darwin Wealth Management LLC bought a new stake in Danaher in the 3rd quarter worth about $55,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.